deep_research/skills/search-strategy/SKILL.md

name, description

name	description
search-strategy	生物医药深度研究的统一检索策略。规定信源优先级、检索轮次、关键词构造、API 路由，以及何时切换到专业信源。所有做信息收集的 worker/agent 必须加载此技能。

Search Strategy

Core Rule

Do not send Chinese chapter titles, interview paragraphs, or full task-card text directly to search APIs. For formal search, first convert the task into short English query terms plus axis terms, then add source/domain constraints when useful.

Query Construction

Build every query from three parts:

• entity/domain: the object or field, such as pharmaceutical, biologics, sterile drug, CDMO, quality system.
• axis: the research axis, such as CAPA deviation change control, aseptic processing process validation PPQ, quality metrics management review.
• evidence type: the evidence to retrieve, such as Warning Letter, meeting materials, guidance, systematic review, patent, best practices.

Default English query length is 5-12 keywords. Chinese terms are useful for NMPA, local industry sources, and internal-material matching, but Chinese long sentences must not be the default query form.

For route-specific searches, do not append the original Chinese chapter title after the English query. If chapter context is needed, map the chapter to short English concept terms first, such as commercial readiness phase gate, aseptic processing, quality metrics management review, or CAPA effectiveness check.

Route Patterns

• fda: use site:fda.gov plus Warning Letter, inspection, enforcement, meeting materials, or meeting minutes, then add the axis terms.
• scholar: use technical/scientific terms plus review, validation, risk management, quality system, or disease/mechanism terms.
• evidence: use Exa highlights for controlled evidence discovery when a packet needs concise source-level excerpts; still trace important hits back to original Tier 1-2 sources.
• patents: use technology route plus material, target, process, formulation, device, or manufacturing terms.
• news: use company/industry plus event type and recency terms.
• general: use Tavily/Exa/Brave for discovery and gap filling; trace useful hits back to Tier 1-2 original sources before citing. Do not route generic web discovery through Serper by default.
• tavily_research conceptually means a phase-level scan, not a normal packet route. Save the research result, score/deduplicate sources, then convert it into candidate evidence before writing claims.

GMP/FDA Examples

Bad query:

围绕《审计发现应先转化为商业化阶段门缺口，而不是停留在风险项计数》从质量体系角度提炼可证伪的核心结论

Good queries:

site:fda.gov "Warning Letter" CGMP CAPA deviation change control data integrity pharmaceutical
site:fda.gov "meeting materials" "pharmaceutical quality" "quality metrics"
site:fda.gov/inspections-compliance-enforcement-and-criminal-investigations "Warning Letter" aseptic processing process validation

Source Priority

• Tier 1: regulator, guideline, pharmacopeia, primary literature, trial registry, patent original, company filing.
• Tier 2: systematic review, recognized consulting or industry association report, professional database/media.
• Tier 3: conference abstract, broker report, preprint, vendor white paper.
• Tier 4: generic web search result; discovery only, not conclusion support.

Four-Round Search Discipline

1. Tier 1 direct hit: regulator, PubMed/Scholar, trial registry, patent original, or official filing.
2. Tier 2 synthesis: recognized review, guideline interpretation, consulting/association report.
3. Counter-evidence: limitations, failures, enforcement actions, contradictory interpretations.
4. Gap fill: Exa evidence discovery or Tavily/Brave general discovery, then trace back to original sources. Use Serper here only for Google-specific needs such as site: targeting, Scholar, Patents, or News.

Tavily Research vs Exa Evidence

• Tavily Research is best for Phase 1 initial landscape scans, thin-chapter补证据, and Phase 3回炉. Prompt in English, specify source priority, counter-evidence, and structured output. Do not cite its synthesized prose directly.
• Exa evidence discovery is best for Phase 2 packet work because highlights/text are compact enough for source-quality scoring and evidence-table mapping.
• Serper remains preferred for Scholar, Google Patents, News, and Google-specific site: targeting.
• Brave remains a cross-check and mixed-language fallback, not the first evidence route.

Required Packet Behavior

• Put search keywords or route notes in raw_quotes_or_notes when evidence is weak or no suitable source was found.
• FDA/GMP tasks must explicitly check Warning Letters, inspection/enforcement pages, and meeting materials/minutes.
• Do not cite search snippets as final evidence when an original regulator, guideline, paper, or official PDF can be reached.
• If the candidate sources are not sufficient, stop and record the gap in open_questions instead of writing generic prose.